BreastCheck expands screening to trans, non-binary patients with hormone requirements
The Irish national breast cancer screening programme, BreastCheck, will invite transgender women, non-binary and intersex people who were registered male at birth to take part in screening, provided they have been taking feminising hormones for more than five years and have breasts or breast tissue. The policy was disclosed by Fiona Murphy, chief of the National Screening Service, in response to a parliamentary question from Independent TD Carol Nolan, who criticised the approach as treating biological sex as "irrelevant" despite breast cancer risk being largely sex-based, calling it a form of "institutional capture" of women's healthcare.
Ms Murphy said the decision followed a review of clinical evidence and international guidelines, alongside consultation with LGBTQI+ organisations, and that BreastCheck staff had received awareness training. She noted the approach broadly mirrors practice in Britain's NHS and reflects guidance from the American College of Radiology on elevated cancer risk among trans women on long-term hormone therapy. The disclosure comes amid separate concerns about BreastCheck's capacity, after it screened 137,134 people in 2024 against a target of 195,000, and 166,532 against a target of 185,000 in 2023, shortfalls partly blamed on a global shortage of radiographers and radiologists.
- BreastCheck now screens trans women after five-plus years of feminising hormones
- TD Carol Nolan says policy erases biological sex in women's health
- BreastCheck also missed 2023 and 2024 screening targets significantly
New here? Start with this
BreastCheck is Ireland's national programme for screening women for breast cancer, run by the National Screening Service. It routinely invites people within a certain age range for regular mammograms, on the basis that this group faces a meaningfully higher risk of the disease.
The story concerns a change to who can be invited for screening. BreastCheck will now also invite transgender women, non-binary and intersex people who were registered male at birth, provided they have been on feminising hormone therapy for more than five years and have breast tissue, reflecting guidance used elsewhere, including in the NHS in Britain and by the American College of Radiology, on cancer risk linked to long-term hormone use.
The change has become a matter of public debate because it touches on wider disagreements about how sex and gender should be treated in healthcare policy, with some parliamentarians and commentators questioning the approach while health officials point to clinical evidence and guidelines used internationally. It also comes at a time when BreastCheck has separately been missing its screening targets in recent years, a capacity issue linked to a shortage of specialist staff.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Advocates for the policy argue that eligibility for cancer screening should follow demonstrated physiological risk rather than the sex recorded at birth: trans women who have taken feminising hormones for over five years develop breast tissue that carries a genuine, elevated cancer risk, as reflected in guidance from bodies such as the American College of Radiology and in NHS practice. On this view, excluding people with clinically relevant breast tissue from a screening programme designed to catch that very cancer would be a failure of preventive medicine, not a defence of its integrity. They would add that the decision followed a structured review of clinical evidence and consultation with relevant patient groups, and that staff training was introduced to support safe, informed delivery rather than being imposed without preparation.
The case against
Critics, including Deputy Nolan, argue that breast cancer risk is overwhelmingly driven by factors tied to female biology, such as age, reproductive history and genetics, and that a national screening programme should keep that sex-based risk profile central to how it targets and communicates with patients. They contend that BreastCheck's demonstrable capacity problems, having missed its screening targets by tens of thousands of patients in both 2023 and 2024 amid staff shortages, make this an especially fraught moment to widen eligibility criteria, since any additional demand not matched by extra capacity could lengthen waits for the group historically most at risk. They further hold that a change of this significance for a women's health service ought to be shaped through open public and parliamentary scrutiny rather than settled primarily through internal review and advocacy group consultation, so that the rationale and its trade-offs are fully tested before implementation.
Business Companies Health Medicine World
Read the full article at the source →
Originally published by Daily Mail as “Trans women as well as non-binary and intersex people can now access the lifesaving cancer-screening service – but only on this ONE condition CEO of BreastCheck confirms”.
Discussion